Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0ZJXEW
ADC Name
16A5-MCC-DM1
Synonyms
16A5 MCC DM1
   Click to Show/Hide
Drug Status
Phase 1
Indication
In total 2 Indication(s)
Breast cancer [ICD11:2C60-2C65]
Phase 1
Non Hodgkin lymphoma [ICD11:2B33]
Phase 1
Drug-to-Antibody Ratio
3.7
Structure
Antibody Name
MBH-1309
  Antibody Info 
Antigen Name
Lymphocyte antigen 75 (LY75)
  Antigen Info 
Payload Name
Mertansine DM1
  Payload Info 
Therapeutic Target
Microtubule (MT)
  Target Info 
Linker Name
Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)
  Linker Info 
Conjugate Type
Random conjugation through nucleophilic lysines.
Combination Type
Emtansine
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 2 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Tumor Growth Inhibition value (TGI) 
≈ 59.9
%
Raji cells
EBV-related Burkitt lymphoma
Tumor Growth Inhibition value (TGI) 
≈ 77.1
%
Pancreatic cancer cells
Pancreatic cancer
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 59.90% (Day 25) High CD205 expression (CD205+++; IHC 3+)
Method Description
The antitumor activity of the ADCs was then evaluated in solid and hematologic mouse xenograft models. A total of 5x106-2x107 cells with or without Matrigel, were injected subcutaneously into the flanks of mice. The treatments were started when average tumor volume reached 88-300 mm3. Animals were randomly assigned into groups (6 mice/group), and treated with MEN1309/OBT076 intravenously once weekly for 2 consecutive weeks, 10 mg/kg.

   Click to Show/Hide
In Vivo Model Diffuse Large B-Cell Lymphoma CDX model
In Vitro Model EBV-related Burkitt lymphoma Raji cells CVCL_0511
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 77.10% (Day 25) High CD205 expression (CD205+++; IHC 3+)
Method Description
The antitumor activity of the ADCs was then evaluated in solid and hematologic mouse xenograft models. A total of 5x106-2x107 cells with or without Matrigel, were injected subcutaneously into the flanks of mice. The treatments were started when average tumor volume reached 88-300 mm3. Animals were randomly assigned into groups (6 mice/group), and treated with MEN1309/OBT076 intravenously with a single dose, 10 mg/kg.

   Click to Show/Hide
In Vivo Model Pancreas cancer CDX model
In Vitro Model Pancreatic cancer Pancreatic cancer cells Homo sapiens
References
Ref 1 Preclinical Development of ADCT-601, a Novel Pyrrolobenzodiazepine Dimer-based Antibody-drug Conjugate Targeting AXL-expressing Cancers. Mol Cancer Ther. 2022 Apr 1;21(4):582-593.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.